[CAS NO. 724741-75-7] STF-31
PRODUCTS SPECIFICATIONS [724741-75-7]
DESCRIPTION [724741-75-7]
Overview
| MDL | MFCD04153828 |
|---|---|
| Molecular Weight | 423.53 |
| Molecular Formula | C23H25N3O3S |
| SMILES | O=C(NC1=CC=CN=C1)C2=CC=C(CNS(=O)(C3=CC=C(C(C)(C)C)C=C3)=O)C=C2 |
6 Publications Citing Use of MCE
Summary
IC50 & Target
|
GLUT1 1 μM (IC 50 ) |
In Vitro
STF-31 (0.01-10 μM; 10 days) is specifically toxic to RCC4 cells, whereas RCC4/VHL cells are relatively unaffected. RCC4/VHL cells treated with STF-31 (5 μM; 10 days) largely recovery, whereas RCC4 cells under the same conditions does not
[1]
.
STF-31 (1.25-5 μM; 3 days) does not induce autophagy, apoptosis, or DNA damage. STF-31 causes a necrotic cell death
[1]
.
STF-31 reduces the efferocytosis of wild type and SLC2A1-overexpressing LR73 cells
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | Wild-type RCC4 cells (RCC4/VHL) and RCC4 cells without VHL |
| Concentration: | 0.01, 0.1, 1, 10 μM |
| Incubation Time: | 10 days |
| Result: | Reduced viability of RCC4 cells without VHL in a concentration-dependent manner when compared to their wild-type counterparts. |
In Vivo
STF-31 (10 mg/kg; i.p.; twice daily for 2 days, followed by once daily for another 3 days) does not affect normal mice body weight, behavior, and ERG responses. STF-31 reduces light-induced
CX3CR1
gfp/+
mice microglial activation and retinal degeneration
[3]
.
STF-31 (10 mg/kg; i.p.) promotes accumulation of necrotic thymocytes after Dexamethasone-induced apoptosis in vivo
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Twelve-week old C57BL/6J and CX3CR1 gfp/+ mice [3] |
| Dosage: | 10 mg/kg |
| Administration: | I.p. injections; twice daily for 2 days, followed by once daily for another 3 days |
| Result: | Improved photoreceptor survival and reduced microglial activation of CX3CR1 gfp/+ mice, and not induced any C57BL/6J mice retinal cell death. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 34 mg/mL ( 80.28 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3611 mL | 11.8055 mL | 23.6111 mL |
| 5 mM | 0.4722 mL | 2.3611 mL | 4.7222 mL |
| 10 mM | 0.2361 mL | 1.1806 mL | 2.3611 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution
References
- [1] Chan DA, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011 Aug 3;3(94):94ra70.
- [2] Dedda CD, et al. Pharmacological Targeting of GLUT1 to Control Autoreactive T Cell Responses. International Journal of Molecular Sciences. 2019 Oct 8; 20(19):4962.
- [3] Wang L, et al. Glucose transporter 1 critically controls microglial activation through facilitating glycolysis. Molecular Neurodegeneration, 2019 Jan 11; 14(1):2.
- [4] Morioka S, et, al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. Nature. 2018 Nov;563(7733):714-718.